Yuta Nakamura

assistant professor

Nagasaki University

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yuta Nakamura is an assistant professor at Nagasaki University in Japan. His research focuses on the effects of therapies for diabetes management, particularly in relation to glucagon secretion and glycemic control. Recent studies include investigations into the efficacy of ipragliflozin, 5-aminolevulinic acid, and the metabolic responses in type 1 and type 2 diabetes patients.

Articles (7)

Year:

2025

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (4)

Tadahiro Kitamura

JAPAN

View details

Ichiro Horie

Nagasaki University

JAPAN

View details

Yushi Hirota

Kobe University Graduate School of Medicine

JAPAN

View details

Shinya Furukawa

Prof.

Ehime University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yuta Nakamura

Research Interests

Explore related searches

Contact this professor

About

Articles (7)

Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study

Pilot Trial on the Effect of 5-Aminolevulinic Acid on Glucose Tolerance in Patients with Maternally Inherited Diabetes and Deafness

Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID)

Study of glucagon response and its association with glycemic control and variability after administration of ipragliflozin as an adjunctive to insulin treatment in patients with type 1 diabetes (Suglat-AID)

A single-arm, open-label, intervention study to investigate the improvement of glucose tolerance after administration of the 5-aminolevulinic acid (5-ALA) in the patients with mitochondrial diabetes mellitus.

Collaborators (4)

Tadahiro Kitamura

Ichiro Horie

Yushi Hirota

Shinya Furukawa

Make your next move.